The Pulse of Healthcare: Weight-Loss Drugs and Big Pharma Moves

The latest health sector updates cover a range of topics: Eli Lilly's weight-loss drug Foundayo draws investor interest despite sales data unavailability, while Bristol Myers outperformed expectations with cancer drug sales. LEO Pharma is acquiring drug developer Replay, and the U.S. Supreme Court has sided with anti-abortion centers in a New Jersey case.

Eli Lilly investors are eagerly anticipating insights into the launch of their new weight-loss pill, Foundayo, which entered the U.S. market in early April. Sales data from this initial period won't appear in the first-quarter financials, requiring more time to gauge the drug's market trajectory.

Meanwhile, LEO Pharma has announced plans to acquire U.S. drug developer Replay for $50 million upfront. This deal aims to enhance LEO's dermatology business with Replay's experimental treatment platform for rare genetic skin diseases.

Additionally, Bristol Myers Squibb has reported financial results that exceed Wall Street expectations, led by strong sales of its blood thinner Eliquis and newer cancer drugs, prompting a rise in shares by 4%.